Back to MRK Stock Lookup

Merck (MRK) – Company Press Releases

Jul 29, 2014 06:56 AM Merck Announces Second-Quarter 2014 Financial Results
Jul 29, 2014 02:30 AM EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma
Jul 24, 2014 08:30 AM Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients
Jul 23, 2014 12:15 PM Merck Announces Fourth-Quarter 2014 Dividend
Jul 17, 2014 08:30 AM Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be "Vocal" about t
Jul 8, 2014 09:00 AM EMD Serono Participates in Global Grants Program to Fund Scientific Innovation and Medical Education
Jul 1, 2014 09:00 AM EMD Serono Commits EUR 2 million to the Grant for Fertility Innovation (GFI) for 2014 /15
Jun 30, 2014 08:00 AM Merck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy
Jun 30, 2014 06:00 AM Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
Jun 30, 2014 06:00 AM MSD’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
Jun 26, 2014 08:00 AM Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
Jun 24, 2014 07:30 AM EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates
Jun 23, 2014 05:00 PM Merck to Hold Second-Quarter 2014 Sales and Earnings Conference Call on July 29
Jun 23, 2014 08:00 AM Merck Names Michael J. Holston as Future General Counsel; Will Succeed Bruce N. Kuhlik in July 2015
Jun 20, 2014 07:30 AM Merck Begins Tender Offer to Acquire Idenix
Jun 13, 2014 08:00 AM Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes
Jun 11, 2014 09:00 AM EMD Serono Launches Compassionate Corps Program to Reduce Cost of Fertility Treatment for Eligible Military Veterans and their Spouses
Jun 9, 2014 07:30 AM Merck to Acquire Idenix
Jun 6, 2014 08:00 AM Merck to Present New Clinical Data on JANUVIA® (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabe
Jun 6, 2014 08:00 AM MSD to Present New Clinical Data on Sitagliptin, Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Associatio
Jun 5, 2014 05:00 PM First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir)
Jun 2, 2014 07:30 AM First Presentation of Data for Pembrolizumab, Merck’s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014
Jun 2, 2014 07:30 AM Data on Merck’s Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014
Jun 1, 2014 09:23 AM First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014
May 29, 2014 02:30 AM EMD Serono to Release New Pipeline Data at ASCO 2014 from Early-Stage Investigational Compounds in Difficult-to-Treat Cancers
May 28, 2014 09:00 AM EMD Serono Data at CMSC & ACTRIMS Annual Meeting Reinforces Proven Efficacy of Rebif® (interferon beta-1a) and Demonstrates Continued Commitment to Patients with Relapsing MS
May 27, 2014 12:21 PM Merck Announces Third-Quarter 2014 Dividend
May 20, 2014 08:00 AM Merck Animal Health Announces FDA Approval of BRAVECTO™ (fluralaner)
May 19, 2014 05:00 PM Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe
May 14, 2014 08:00 AM Merck’s Investigational Anti-PD1 Antibody, MK-3475, Active in Three Different Tumor Types: New Data to be Presented at the 2014 ASCO Annual Meeting
May 13, 2014 02:15 AM Merck Signs Sale Agreement with Santen for Merck’s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific
May 12, 2014 07:30 AM FDA Approves ZONTIVITY™ (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Dis
May 8, 2014 09:00 AM AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients
May 6, 2014 08:59 AM Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&D Focus; Drive Growth and Productivity
May 6, 2014 08:40 AM Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma
May 6, 2014 06:00 AM Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion
May 2, 2014 08:00 AM Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis

Back to MRK Stock Lookup